SCHEMBL2655735

SCHEMBL2655735

CC(=O)c1ccc(Nc2cccc(N3CCN(C(C)=O)CC3)c2)c(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
HTT P42858 1/20 0.48
POLB P06746 1/20 0.47
LMNA P02545 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CCNT1 O60563 3/20 0.46
CCNA2 P20248 3/20 0.46
CDK2 P24941 3/20 0.46
CDK9 P50750 3/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
CDK7 P50613 1/20 0.46
CCNH P51946 1/20 0.46
GAA P10253 2/20 0.46
GFER P55789 2/20 0.46
NPC1 O15118 2/20 0.46
ALDH1A1 P00352 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2665512 0.90 CNR1 (0.52) MAPTPOLBRXFP1KMT2AMEN1
SCHEMBL2653555 0.88 NPC1 (0.49) MAPTLMNASMN1; SMN2CCNT1CCNA2
SCHEMBL8259892 0.85 GAA (0.45) MAPTHTTPOLBLMNAGAA
SCHEMBL2655693 0.85 GAA (0.52) MAPTPOLBLMNAKMT2AMEN1
SCHEMBL2653592 0.84 MAPT (0.43) MAPTRXFP1SMN1; SMN2CCNT1CCNA2
SCHEMBL2656292 0.84 LMNA (0.52) MAPTHTTPOLBLMNAKMT2A
SCHEMBL2648721 0.83 MAPT (0.50) MAPTHTTPOLBLMNAKMT2A
SCHEMBL2655224 0.83 CCNT1 (0.45) MAPTHTTLMNAKMT2AMEN1
SCHEMBL4199937 0.81 SCN9A (0.45) MAPTLMNASMN1; SMN2CCNT1CCNA2
SCHEMBL4202254 0.81 KDM4E (0.42) MAPTHTTPOLBLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062304-A1 Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex NEUROSEARCH A/S (DK) 2009-03-05 US disclosed
EP-1874735-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP disclosed
WO-2006111517-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO disclosed
EP-1194410-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2006-01-18 EP disclosed
US-6936613-B2 Benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUROSEARCH A/S (DK) 2005-08-30 US disclosed
CN-1167686-C Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds О 2004-09-22 CN disclosed
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUROSEARCH A/S 2004-05-20 US disclosed
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUROSEARCH A/S 2004-05-20 US disclosed
US-6649609-B2 For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children NEUROSEARCH A/S (DK) 2003-11-18 US disclosed
US-20030055055-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds ANIONA APS (DK) 2003-03-20 US disclosed
CN-1356987-A Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds NEUROSEARCH AS (DK) 2002-07-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062304-A1 Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex GABRB1, GABRB2, GABRB3 MAPT 1260/4885HTT 2412/4885POLB 4058/4885
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA1, GABRA2, GABRA4 MAPT 906/4885HTT 3830/4885POLB 4499/4885
US-20030055055-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA1, GABRA2, GABRA4 MAPT 981/4885HTT 3789/4885POLB 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.